Close Menu

PD-L1 Biomarkers

News and reporting on PD-L1 biomarkers.

The results are of interest to drugmakers looking for scalable technology solutions for assessment of PD-L1 for predicting immunotherapy response.

Promega's microsatellite instability technology will be used to develop an on-label, solid tumor companion diagnostic for pembrolizumab.

A new study suggests that using rotavirus in combination with immune checkpoint blockade therapy could give oncologists a new way to treat pediatric cancers.

The European Commission will review CHMP's recommendation and is slated to issue a final decision regarding marketing authorization later this year.

In KEYNOTE-522, early-stage TNBC patients on the immunotherapy and chemotherapy combination benefitted regardless of their PD-L1 expression status.  

The assay was developed in partnership with Merck and is intended as a companion diagnostic for that firm's anti-PD-L1 immunotherapy.

IMvigor130 data suggests atezolizumab plus chemotherapy delays progression in urothelial carcinoma, with potential survival benefit seen in PD-L1 subgroup treated with monotherapy.

A collection of biomarker- and genomic testing-driven precision oncology research presented at the European Society of Medical Oncology Congress.

Two KEYNOTE studies showed TMB may have some utility in determining which NSCLC patients should get pembrolizumab, while three others showed no utility.

Results from the CheckMate-227 trial provided evidence for the use of nivolumab and ipilimumab in combination, while the FLAURA study focused on osimertinib.

Pages